Who are in the management team of Guj. Inject(Ker)?

As of March 2022, the management team of Guj. Inject(Ker) includes Murli Shivshankaran Nair (Whole Time Director & CFO), Reena Mahatma (Director), and independent directors Narayansinh Padudansinh Chauhan and Gautam Keshavlal Chauhan.

As of March 2022, the management team of Guj. Inject(Ker) includes:<BR><BR>1. Murli Shivshankaran Nair - Whole Time Director & CFO<BR>2. Reena Mahatma - Director<BR>3. Narayansinh Padudansinh Chauhan - Independent Director<BR>4. Gautam Keshavlal Chauhan - Independent Director<BR><BR>These individuals comprise the board of directors overseeing the company's operations.

Has Guj. Inject(Ker) declared dividend?

No Dividend History Available

Who are the peers of the Guj. Inject(Ker)?

Peers of Guj. Inject(Ker) include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Guj. Terce Labs and others exhibit below-average performance.

Peers: The peers of Guj. Inject(Ker) are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, and Vilin Bio Med.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Below Average management risk is found at Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, and Vilin Bio Med. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Divi's Lab., Torrent Pharma, Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, Concord Drugs, and Vilin Bio Med. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average capital structure is present at Guj. Terce Labs., ANG Lifesciences, Concord Drugs, and Vilin Bio Med.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while ANG Lifesciences has the lowest at -44.35%. Guj. Inject(Ker) does not have a 1-year return available for comparison. Additionally, Guj. Terce Labs., ANG Lifesciences, Shree Ganesh Bio, and Vilin Bio Med all have negative six-month returns.

What is the technical trend for Guj. Inject(Ker)?

As of May 22, 2025, the technical outlook is mildly bullish, supported by daily moving averages and KST indicators, despite mixed signals from the Bollinger Bands and a bearish weekly MACD.

As of 22 May 2025, the technical trend has changed from sideways to mildly bullish. The daily moving averages indicate a bullish stance, while the weekly MACD shows a mildly bearish trend. The Bollinger Bands present a mixed view with a bearish signal on the weekly and a mildly bullish signal on the monthly. The KST is bullish on the weekly timeframe, supporting the mildly bullish outlook. However, the weekly Dow Theory indicates a bullish trend, while the monthly shows no trend. Overall, the current technical stance is mildly bullish, driven primarily by daily moving averages and KST indicators.

Why is Guj. Inject(Ker) falling/rising?

As of 10-Jun, Gujarat Inject (Kerala) Ltd's stock price is 22.80, reflecting a slight increase of 0.31%. Despite a strong performance over the past year, recent trends show a decline in investor participation and mixed short-term performance, with a 9.92% drop over the past week.

As of 10-Jun, Gujarat Inject (Kerala) Ltd is experiencing a slight increase in its stock price, currently at 22.80, with a change of 0.07, representing a 0.31% rise. The stock has shown mixed performance in recent periods, with a notable decline of 9.92% over the past week, while it has increased by 22.06% over the past month. However, it is important to note that the stock's delivery volume has significantly decreased by 60.55% compared to the 5-day average, indicating falling investor participation. Additionally, while the stock is currently above its 200-day moving average, it remains below the shorter-term moving averages, suggesting some volatility in its price movements.<BR><BR>In the broader market context, the Sensex has gained 2.05% over the past week and 3.70% over the past month, indicating that Gujarat Inject's recent decline is not in line with the overall market trend. Year-to-date, the stock has underperformed the benchmark, with a decline of 10.20% compared to the Sensex's gain of 5.44%. Despite a strong performance over the past year, with a 36.28% increase, the recent short-term trends and declining investor participation may be contributing to the stock's current price dynamics.

What does Guj. Inject(Ker) do?

Gujarat Inject (Kerala) Ltd is a micro-cap pharmaceutical company specializing in I.V. fluids, with a market cap of INR 34 Cr and reported net sales of 42 Cr and net profit of 1 Cr for the quarter ending March 2025. The company has no debt and a dividend yield of 0%.

Overview:<BR>Gujarat Inject (Kerala) Ltd is a micro-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the production of I.V. fluids.<BR><BR>History:<BR>The company was incorporated in January 1991 and began production of I.V. fluids in April 2005. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 42 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 34 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.00<BR>- Return on Equity: 0.00%<BR>- Price to Book: 0.00<BR><BR>Contact Details:<BR>Address: Bldg No XVII/1103 Kanjikode, Sarayu Arcade Satrapadi Palakkad Kerala : 678621<BR>Website: http://www.gujaratinject.com

Who are the top shareholders of the Guj. Inject(Ker)?

The top shareholders of Guj. Inject(Ker) are mainly individual investors, holding 83.95% of shares, with Jignesh Shivlal Makasana as the largest public shareholder at 11.95%. There are no institutional holdings or pledged promoter shares.

The top shareholders of Guj. Inject(Ker) are primarily individual investors, who hold a significant 83.95% of the shares. Among public shareholders, Jignesh Shivlal Makasana stands out with a holding of 11.95%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings. The majority of the shares are held by non-institutional entities.

How big is Guj. Inject(Ker)?

As of 24th July, Gujarat Inject (Kerala) Ltd has a market capitalization of 35.00 Cr, classifying it as a Micro Cap company, with recent Net Sales of 19.05 Cr and a Net Profit of 1.01 Cr; specific values for Shareholder's Funds and Total Assets are unavailable.

As of 24th July, Gujarat Inject (Kerala) Ltd has a market capitalization of 35.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 19.05 Cr and a Net Profit of 1.01 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period, but specific values for Shareholder's Funds and Total Assets are unavailable.

When is the next results date for Guj. Inject(Ker)?

The next results date for Guj. Inject(Ker) is 13 November 2025.

The next results date for Guj. Inject(Ker) is scheduled for 13 November 2025.

How has been the historical performance of Guj. Inject(Ker)?

Guj. Inject(Ker) has shown significant growth from March 2022 to March 2025, with net sales increasing from 0.02 crore to 19.05 crore and operating profit turning positive at 1.26 crore. The company also improved its profit before tax to 1.25 crore and earnings per share rose to 0.7, indicating strong revenue and profitability growth.

Answer:<BR>The historical performance of Guj. Inject(Ker) shows significant growth in net sales and profitability over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Guj. Inject(Ker) experienced a remarkable increase in net sales, rising from just 0.02 crore in March 2022 to 19.05 crore in March 2025. This growth is reflected in total operating income, which also surged from 0.02 crore in March 2022 to 19.05 crore in March 2025. The company's total expenditure, excluding depreciation, increased from 0.07 crore in March 2022 to 17.97 crore in March 2025, indicating a rise in operational costs alongside revenue growth. Operating profit, which was negative in earlier years, turned positive, reaching 1.26 crore in March 2025, with an operating profit margin of 5.67%. Profit before tax also improved significantly, from 0.00 crore in March 2022 to 1.25 crore in March 2025, leading to a profit after tax of 1.02 crore in the same period. The earnings per share (EPS) rose from 0.0 in March 2022 to 0.7 in March 2025, showcasing enhanced shareholder value. Overall, the financial data indicates a strong upward trend in both revenue and profitability for Guj. Inject(Ker) over the analyzed period.

Which are the latest news on Guj. Inject(Ker)?